Skip to main content

Table 2 Pharmacological pattern and cost per cycle

From: Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain

Treatment Cost/mg ** Dosage/(mg/m 2)† Days of treatment/cycle Cost per cycle
AZA REGIMEN
Azacitidine €3.40/mg 75 7 €3,028.14
LDC REGIMEN
Cytarabine €0.0271/mg 150 7 €48.38
SDC REGIMEN*
Cytarabine/Idarubicin     €965.16
Cytarabine €0.0271/mg 1000 7 €322.56
Idarubicin €10.52/mg 12 3 €642.60
Cytarabine/Mitoxantrone     €543.55
Cytarabine €0.0271/mg 1000 7 €322.56
Mitoxantrone €3.62/mg 12 3 €220.99
Cytarabine/Daunorubicin     €377.12
Cytarabine €0.0271/mg 1000 7 €322.56
Daunorubicin €0.179/mg 60 3 €54.56
Cytarabine/Idarubicin/Etoposide     €848.68
Cytarabine €0.0271/mg 1000 4 €184.32
Idarubicin €10.52/mg 12 3 €642.60
Etoposide €0.043/mg 100 3 €21.76
  1. Abbreviations: AZA = azacitidine; LDC = low dose chemotherapy; SDC = standard dose chemotherapy.
  2. * Data were pooled corresponding to Spanish usual care weight for each treatment (pooled cost: €790. 41). ** All costs are expressed in ex-factory price and are discounted according to RD 15/2010 † Mean body surface was assumed to be 1.7 m2.